Diabetes and diabetic complications

Novo Nordisk - Kidney disease

In August 2020, Evotec and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.

Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients. The collaboration intends to pursue the most relevant human disease biology in a therapeutic modality-agnostic approach to develop first-in-class therapeutics for patients suffering from CKD.

Under the terms of the agreement, Evotec and Novo Nordisk will share responsibilities during drug discovery and pre-clinical development. Novo Nordisk will be responsible for the clinical development and commercialisation of the products. Evotec will receive an undisclosed upfront payment, research funding and milestone potential of more than € 150 m per product as well as tiered royalties on net sales.

Bayer/ CureNephron

In September 2016, Evotec announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates.

Under the terms of the agreement, Bayer received exclusive access to selected candidates as well as to Evotec’s CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive a minimum of € 14 m over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 m as well as tiered royalties of up to low double-digit percentage of net sales. 

TOP